Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Akero’s lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 agonist and potential best-in-class treatment for NASH. AKR-001 builds upon two decades of work on FGF21 biology and is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis. Akero went public in June 2019 (NASDAQ: AKRO).
| Headquarters | Cambridge, MA |
| Website | www.akerotx.com |
| @akerotx | |
| Pipeline | Clinical |